6 Spam-Free Article(s) Found
Sort:
Date
Filter:
7d
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B Downtrend
Article Searches
Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2018 http://www.gurufocus.com/news/817582/allergan-plc-agn-files-10k-for-the-fiscal-year-ended-on-december-31-2018 Feb 15, 2019 - Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2018, Stocks: AGN, release date:Feb 15, 2019
Diamond Hill Buys AIG, CVS http://www.gurufocus.com/news/817266/diamond-hill-buys-aig-cvs Feb 15, 2019 - Diamond Hill Buys AIG, CVS, Stocks: AIG,CVS,GM,C,AGN,OZK, release date:Feb 15, 2019
FDA Panel Nod for J&J's Esketamine Is Good News for Allergan, Vistagen http://www.gurufocus.com/news/815653/fda-panel-nod-for-jjs-esketamine-is-good-news-for-allergan-vistagen Feb 14, 2019 - FDA Panel Nod for J&J's Esketamine Is Good News for Allergan, Vistagen, Stocks: JNJ,AGN,VTGN, release date:Feb 14, 2019
Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down http://www.zacks.com/stock/news/354559/teva-teva-q4-earnings-miss19-view-weak-shares-down?cid=CS-ZC-FT-354559 Feb 14, 2019 - Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.
Financial Exchange Stock Talk: Joe McCann On Aurinia Pharmaceuticals https://seekingalpha.com/article/4240199-financial-exchange-stock-talk-joe-mccann-aurinia-pharmaceuticals?source=feed_tag_editors_picks Feb 12, 2019 - We now partner with Financial Exchange Radio to produce a weekly segment with Seeking Alpha authors.Joe McCann continues the series with his bullish pick: Aurinia Pharmaceuticals.Aurinia recently repo
Goldman Sachs is backing off the investing thesis it's held for the past two years https://www.cnbc.com/2019/02/11/goldman-is-closing-the-investing-thesis-its-held-for-the-past-2-years.html Feb 11, 2019 - With the Fed nearing the end of its policy tightening, Goldman thinks it's time for investors to change strategy and shift to weak balance sheets.

Pages: 1

Page 1

Related Companies

Name Exchange Price Mkt Cap
CELG Celgene Corporation NASDAQ $87.23 $61.35B
SHPG Shire plc NASDAQ $176.25 $46.08B
VRTX Vertex Pharmaceuticals Incorporated NASDAQ $175.8 $44.93B
ZTS Zoetis Inc. NYSE $88.3 $42.55B
REGN Regeneron Pharmaceuticals, Inc. NASDAQ $386.665 $41.78B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Allergan plc.
AGN - Google Finance https://www.google.com/finance?q=AGN Industry related info and international coverage Summary News
AGN - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=AGN Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options